In clinical trials, whilst patients from several tumor types have shown responses to MEK inhibitor monotherapy, other patients' tumors, particularly non-small cell lung cancers, are inherently resistant to MEK inhibition. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.